| 2.82 0.02 (0.71%) | 12-08 15:11 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.62  |
1-year : | 4.32 |
| Resists | First : | 3.1 |
Second : | 3.7 |
| Pivot price | 2.85 |
|||
| Supports | First : | 2.14 |
Second : | 1.78 |
| MAs | MA(5) : | 2.84  |
MA(20) : | 2.77 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 38.6 |
D(3) : | 40 |
| RSI | RSI(14): 49.9 |
|||
| 52-week | High : | 6.65 | Low : | 1.79 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NRXS ] has closed above bottom band by 47.4%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 3.07 - 3.09 | 3.09 - 3.11 |
| Low: | 2.69 - 2.72 | 2.72 - 2.74 |
| Close: | 2.78 - 2.82 | 2.82 - 2.86 |
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
Tue, 21 Nov 2023
Neuraxis Reports Decline in Earnings and Sales for Q3 2023 - Best Stocks
Mon, 20 Nov 2023
NeurAxis Reports Third Quarter 2023 Financial Results - Neuraxis (AMEX:NRXS) - Benzinga
Wed, 15 Nov 2023
NeurAxis Announces CareFirst BCBS Policy Coverage - Yahoo Finance
Tue, 14 Nov 2023
NeurAxis Secures $3 Million Financing - Yahoo Finance
Wed, 08 Nov 2023
NeurAxis, Inc. Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device - Marketscreener.com
Thu, 21 Sep 2023
NeurAxis Reports Second Quarter 2023 Financial Results - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|